These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 22348829)

  • 21. Mechanisms underlying resistance to cetuximab in the HNSCC cell line: role of AKT inhibition in bypassing this resistance.
    Rebucci M; Peixoto P; Dewitte A; Wattez N; De Nuncques MA; Rezvoy N; Vautravers-Dewas C; Buisine MP; Guerin E; Peyrat JP; Lartigau E; Lansiaux A
    Int J Oncol; 2011 Jan; 38(1):189-200. PubMed ID: 21109940
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Overcoming radioresistance in head and neck squamous cell carcinoma.
    Yamamoto VN; Thylur DS; Bauschard M; Schmale I; Sinha UK
    Oral Oncol; 2016 Dec; 63():44-51. PubMed ID: 27938999
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The involvement of hypoxia-inducible factor-1alpha in the susceptibility to gamma-rays and chemotherapeutic drugs of oral squamous cell carcinoma cells.
    Sasabe E; Zhou X; Li D; Oku N; Yamamoto T; Osaki T
    Int J Cancer; 2007 Jan; 120(2):268-77. PubMed ID: 17066447
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differential pattern of HIF-1α expression in HNSCC cancer stem cells after carbon ion or photon irradiation: one molecular explanation of the oxygen effect.
    Wozny AS; Lauret A; Battiston-Montagne P; Guy JB; Beuve M; Cunha M; Saintigny Y; Blond E; Magne N; Lalle P; Ardail D; Alphonse G; Rodriguez-Lafrasse C
    Br J Cancer; 2017 May; 116(10):1340-1349. PubMed ID: 28407653
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro study of normoxic epidermal growth factor receptor-induced hypoxia-inducible factor-1-alpha, vascular endothelial growth factor, and BNIP3 expression in head and neck squamous cell carcinoma cell lines: Implications for anti-epidermal growth factor receptor therapy.
    Secades P; de Santa-María IS; Merlo A; Suarez C; Chiara MD
    Head Neck; 2015 Aug; 37(8):1150-62. PubMed ID: 24798801
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Autocrine epidermal growth factor receptor ligand production and cetuximab response in head and neck squamous cell carcinoma cell lines.
    Oshima G; Wennerberg J; Yamatodani T; Kjellén E; Mineta H; Johnsson A; Ekblad L
    J Cancer Res Clin Oncol; 2012 Mar; 138(3):491-9. PubMed ID: 22193422
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Head and neck cancer as a clinical model for molecular targeting of therapy: combining EGFR blockade with radiation.
    Harari PM; Huang SM
    Int J Radiat Oncol Biol Phys; 2001 Feb; 49(2):427-33. PubMed ID: 11173137
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of SphK1 reduces radiation-induced migration and enhances sensitivity to cetuximab treatment by affecting the EGFR / SphK1 crosstalk.
    Schiefler C; Piontek G; Doescher J; Schuettler D; Mißlbeck M; Rudelius M; Haug A; Reiter R; Brockhoff G; Pickhard A
    Oncotarget; 2014 Oct; 5(20):9877-88. PubMed ID: 25245676
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hypoxia induces TFE3 expression in head and neck squamous cell carcinoma.
    Sun ZJ; Yu GT; Huang CF; Bu LL; Liu JF; Ma SR; Zhang WF; Liu B; Zhang L
    Oncotarget; 2016 Mar; 7(10):11651-63. PubMed ID: 26872381
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The epidermal growth factor receptor antibody cetuximab induces autophagy in cancer cells by downregulating HIF-1alpha and Bcl-2 and activating the beclin 1/hVps34 complex.
    Li X; Fan Z
    Cancer Res; 2010 Jul; 70(14):5942-52. PubMed ID: 20634405
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of EGFR or IGF-1R signaling enhances radiation response in head and neck cancer models but concurrent inhibition has no added benefit.
    Raju U; Molkentine DP; Valdecanas DR; Deorukhkar A; Mason KA; Buchholz TA; Meyn RE; Ang KK; Skinner H
    Cancer Med; 2015 Jan; 4(1):65-74. PubMed ID: 25355701
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Acetyl-CoA carboxylase rewires cancer metabolism to allow cancer cells to survive inhibition of the Warburg effect by cetuximab.
    Luo J; Hong Y; Lu Y; Qiu S; Chaganty BK; Zhang L; Wang X; Li Q; Fan Z
    Cancer Lett; 2017 Jan; 384():39-49. PubMed ID: 27693630
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bortezomib sensitizes esophageal squamous cancer cells to radiotherapy by suppressing the expression of HIF-1α and apoptosis proteins.
    Wang D; Qin Q; Jiang QJ; Wang DF
    J Xray Sci Technol; 2016 Apr; 24(4):639-46. PubMed ID: 27080362
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Melittin enhances radiosensitivity of hypoxic head and neck squamous cell carcinoma by suppressing HIF-1α.
    Yang X; Zhu H; Ge Y; Liu J; Cai J; Qin Q; Zhan L; Zhang C; Xu L; Liu Z; Yang Y; Yang Y; Ma J; Cheng H; Sun X
    Tumour Biol; 2014 Oct; 35(10):10443-8. PubMed ID: 25053591
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Autophagy is the main driver of radioresistance of HNSCC cells in mild hypoxia.
    Hill RM; Li C; Hughes JR; Rocha S; Grundy GJ; Parsons JL
    J Cell Mol Med; 2024 Jun; 28(12):e18482. PubMed ID: 38899556
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ASCT2 (SLC1A5) is an EGFR-associated protein that can be co-targeted by cetuximab to sensitize cancer cells to ROS-induced apoptosis.
    Lu H; Li X; Lu Y; Qiu S; Fan Z
    Cancer Lett; 2016 Oct; 381(1):23-30. PubMed ID: 27450723
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of hypoxia-inducible factor-1 alpha radiosensitized MG-63 human osteosarcoma cells in vitro.
    Jin Z; Aixi Y; Baiwen Q; Zonghuan L; Xiang H
    Tumori; 2015; 101(5):578-84. PubMed ID: 26350185
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of TGF-β enhances the in vivo antitumor efficacy of EGF receptor-targeted therapy.
    Bedi A; Chang X; Noonan K; Pham V; Bedi R; Fertig EJ; Considine M; Califano JA; Borrello I; Chung CH; Sidransky D; Ravi R
    Mol Cancer Ther; 2012 Nov; 11(11):2429-39. PubMed ID: 22927667
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inactivation of HNSCC cells by 90Y-labeled cetuximab strictly depends on the number of induced DNA double-strand breaks.
    Saker J; Kriegs M; Zenker M; Heldt JM; Eke I; Pietzsch HJ; Grénman R; Cordes N; Petersen C; Baumann M; Steinbach J; Dikomey E; Kasten-Pisula U
    J Nucl Med; 2013 Mar; 54(3):416-23. PubMed ID: 23345302
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interleukin-1 alpha increases anti-tumor efficacy of cetuximab in head and neck squamous cell carcinoma.
    Espinosa-Cotton M; Rodman Iii SN; Ross KA; Jensen IJ; Sangodeyi-Miller K; McLaren AJ; Dahl RA; Gibson-Corley KN; Koch AT; Fu YX; Badovinac VP; Laux D; Narasimhan B; Simons AL
    J Immunother Cancer; 2019 Mar; 7(1):79. PubMed ID: 30890189
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.